Two Phase Extension Trial of SP668 to Investigate the Safety and Tolerability of Sustained Release Fesoterodine in Subjects With Overactive Bladder: a Double-Blind Phase Followed by an Open-Label Extension Phase.
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2014
At a glance
- Drugs Fesoterodine (Primary)
- Indications Overactive bladder
- Focus Adverse reactions
- Sponsors UCB
- 18 Sep 2006 New trial record.